Akers Biosciences Inc (NASDAQ:AKER) said on Tuesday that its pharmaceutical partner MyMD Pharmaceuticals Inc has signed an agreement with a medical school to conduct a Phase 2 clinical trial of MYMD-1 to treat immune mediated depression in COVID-19 patients.
MyMD Pharmaceuticals Inc and the major medical school will launch a Phase 2 clinical trial to investigate the effectiveness of MYMD-1 to treat immune mediated depression in patients affected with COVID-19, a first of its kind expected therapy.
In a recent finding published in JAMA Network Open, about 52% of individuals who had COVID-19 had an associated moderate to severe Major Depressive Disorder.
Under a contract research agreement, the study is designed to analyze the pro-inflammatory cytokines associated with the cytokine storm, with the Phase 2 trial planned to begin in Q2. The COVID-19 depression trial is expected to be followed by studies at a major medical school on the therapeutic potential of MYMD-1 in patients with multiple sclerosis, including its effects on depression and disease progression.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients